Evidence map›Paper›PMID 40538510›Full record

ArticleWorld journal of gastroenterology2025

Targeting the NAD+/SIRT1 axis: A metabolic strategy to overcome oxaliplatin resistance in colorectal cancer.

Md Sadique Hussain, Vikash Jakhmola, Kavita Goyal, Arcot Rekha, Ayesha Sultana, Haider Ali, Gaurav Gupta

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. The role of NADFrontiers in oncology · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Md Sadique HussainUttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehra Dun 248007, Uttarākhand, India. sadiquehussain007@gmail.com.
Vikash JakhmolaUttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehra Dun 248007, Uttarākhand, India.
Kavita GoyalDepartment of Biotechnology, Graphic Era (Deemed to Be University), Dehra Dun 248002, Uttarākhand, India.
Arcot RekhaDepartment of General Surgery, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pune 411018, Mahārāshtra, India.
Ayesha SultanaDepartment of Pharmaceutics, Sree Dattha Institute of Pharmacy, Hyderabad 501510, Telangāna, India.
Haider AliCentre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 602105, Tamil Nādu, India.
Gaurav GuptaCentre for Research Impact & Outcome-Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxaliplatin resistance remains a significant clinical challenge in colorectal cancer (CRC), highlighting the urgent need to identify novel molecular targets for therapeutic intervention. Recent findings by Niu

Indexed as

Antineoplastic AgentsColorectal NeoplasmsDrug Resistance, NeoplasmNADOxaliplatinSirtuin 1Cell Line, TumorDNA DamageGlycolysisHumansSignal TransductionAntineoplastic AgentsNADOxaliplatinSIRT1 protein, humanSirtuin 1ChemotherapyColorectal cancerDrug resistanceGlycolysisSIRT1

Identifiers

PMID40538510
PMCPMC12175865

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.